NFKB1 and Alzheimer disease: While the use of NF-kB inhibitor(s) and AM directed strategies represent an obvious therapeutic choice in the future clinical management of AD and related neurological disorders for which miRNAs are now known to play critical pathological roles, the delivery systems used to administer these drugs to the AD patient are often complicated and problematic.